Allergy—A New Role for T Cell Superantigens of Staphylococcus aureus? by Abdurrahman, Goran et al.
toxins
Review
Allergy—A New Role for T Cell Superantigens of
Staphylococcus aureus?
Goran Abdurrahman 1, Frieder Schmiedeke 1 , Claus Bachert 2,3, Barbara M. Bröker 1 and
Silva Holtfreter 1,*
1 Department of Immunology, University Medicine Greifswald, 17475 Greifswald, Germany;
goran.abdurrahman@uni-greifswald.de (G.A.); frieder.schmiedeke@uni-greifswald.de (F.S.);
broeker@uni-greifswald.de (B.M.B.)
2 Upper Airways Research Laboratory, Department of Otorhinolaryngology, Ghent University, 9000 Ghent,
Belgium; Claus.Bachert@UGent.be
3 Current address: Department of Medicine Solna, Immunology and Allergy Research Unit, Karolinska
Institute, 171 77 Stockholm, Sweden
* Correspondence: silva.holtfreter@med.uni-greifswald.de; Tel.: +49-3834-86-5518
Received: 15 February 2020; Accepted: 10 March 2020; Published: 12 March 2020


Abstract: Staphylococcus aureus superantigens (SAgs) are among the most potent T cell mitogens
known. They stimulate large fractions of T cells by cross-linking their T cell receptor with
major histocompatibility complex class-II molecules on antigen presenting cells, resulting in T
cell proliferation and massive cytokine release. To date, 26 different SAgs have been described in the
species S. aureus; they comprise the toxic shock syndrome toxin (TSST-1), as well as 25 staphylococcal
enterotoxins (SEs) or enterotoxin-like proteins (SEls). SAgs can cause staphylococcal food poisoning
and toxic shock syndrome and contribute to the clinical symptoms of staphylococcal infection. In
addition, there is growing evidence that SAgs are involved in allergic diseases. This review provides
an overview on recent epidemiological data on the involvement of S. aureus SAgs and anti-SAg-IgE
in allergy, demonstrating that being sensitized to SEs—in contrast to inhalant allergens—is associated
with a severe disease course in patients with chronic airway inflammation. The mechanisms by which
SAgs trigger or amplify allergic immune responses, however, are not yet fully understood. Here, we
discuss known and hypothetical pathways by which SAgs can drive an atopic disease.
Keywords: Staphylococcus aureus; superantigens; T cells; allergy; sensitization; IgE; T cell superallergen
Key Contribution: There is growing evidence for an involvement of S. aureus SAgs in allergies.
Colonization with S. aureus and the presence of IgE antibodies against SAgs (also known as SE-IgE)
are strongly linked with allergic sensitization and severe chronic inflammatory airway diseases. Here,
we discuss possible mechanisms by which SAgs can drive/or exacerbate an allergic immune response.
1. Introduction
Staphylococcus (S.) aureus is a multifaceted human pathobiont. The most frequent encounter
with S. aureus is symptom-free colonization, with 20% of the human population being persistently
colonized, and the remainder being intermittently colonized [1,2]. Moreover, these bacteria cause a
wide spectrum of illnesses, ranging from self-limiting food poisoning and skin and soft tissue infections
to life-threatening diseases, such as pneumonia, endocarditis, and sepsis [3]. In addition, more recent
evidence suggests an unexpected role of S. aureus in allergic diseases [4].
The capability of S. aureus to cause such a broad range of clinical outcomes is based on an abundance
of adhesins, exoenzymes, immune evasion factors, and virulence factors, which facilitate attachment,
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colonization, tissue invasion, toxinosis, immune evasion, and allergic reactions [5]. Superantigens
(SAgs) are the most notorious of this large arsenal of staphylococcal virulence factors. These exotoxins
activate large subpopulations of T lymphocytes, causing a massive cytokine release which may lead to
systemic shock. On top, there is accumulating evidence for a role of SAgs in triggering and amplifying
allergic responses [6].
This review:
(1) Provides an overview on the function and diversity of staphylococcal superantigens (SAgs),
(2) Reports on advances in the development of SAg vaccines,
(3) Summarizes recent epidemiological data on the involvement of SAgs in allergy,
(4) Outlines mechanisms by which SAgs could induce or amplify allergic responses,
(5) Elaborates on the evolutionary advantage gained by the production of SAgs, and finally,
(6) Discusses knowledge gaps that should be addressed in future research.
1.1. SAgs are Extremely Potent T Cell Mitogens
SAgs are the most potent T cell mitogens known. Low picomolar and even femtomolar
concentrations are sufficient to trigger oligoclonal T cell activation, resulting in an immense cytokine
release [6]. Hence, the term “superantigen” seems appropriate [7,8]. In contrast, a B cell SAg, e.g., the
staphylococcal protein A, binds to the B cell receptor and induces polyclonal B cell activation [9]. SAgs
have evolved in parallel not only in different bacteria but also in viruses; the most famous are the
phylogenetically related enterotoxins secreted by S. aureus and Streptococcus pyogenes [10].
The molecular mechanism underlying oligoclonal T cell stimulation by SAgs have been resolved
in the past decades and are elaborated below (Section 3.2). Briefly, SAgs act by circumventing the
physiological antigen processing and presentation pathways. Conventional antigens are engulfed
and processed by antigen presenting cells (APCs, e.g., dendritic cells, B cells, and macrophages). The
generated antigenic peptides are presented on major histocompatibility complex class II (MHC-II)
molecules to CD4+ T cells, which discern the complex via the hypervariable loops of their T cell
receptor (TCR) α and β chains. Only Th cells with complementary receptor specificity are activated,
resulting in clonal expansion, cytokine secretion, and B cell help (Figure 1A). SAgs can short-circuit
this highly specific interaction between APCs and T cells by binding both TCRs and MHC-II molecules
outside of their peptide binding sites (Figure 1B). Hence, T cells are triggered independently of their
antigen specificity, eventually leading to an activation of up to 20% of all T cells. Activated T cells will
strongly proliferate and release large amounts of cytokines, predominantly interleukin (IL)-2, tumour
necrosis factor α (TNF-α), and interferon γ (IFN-γ) [11–13]. This proliferative stage can be followed
by a profound state of T cell exhaustion, i.e., unresponsiveness, or even cell death [13]. On the APC
side, SAg-induced activation can have various outcomes depending on the cell type. In the case of
monocytes for instance, activation is triggered by dimerization of MHC-II molecules and/or signaling
via CD40 leading to the secretion of TNF-α, IL-1β, and IL-6 [11,14–16]. SAgs have also been shown to
inhibit monocyte proliferation [16].
1.2. Staphylococcal SAgs are Highly Diverse
To date, 26 different SAgs have been described in the species S. aureus. They comprise the toxic
shock syndrome toxin (TSST-1), 11 staphylococcal enterotoxins (SEA–SEE, SEG–SEI, SER–SET), as well
as 14 SE-like proteins (SElJ–SElQ, SElU–SElZ). While SEs are toxins with demonstrated emetic activity,
the SEl proteins are not emetic in a primate model or have yet to be tested.
Most SAg genes are encoded on mobile genetic elements (MGEs), such as phages, pathogenicity
islands, and plasmids, which can be exchanged betweenS. aureus isolates by horizontal gene transfer [11].
In contrast, the enterotoxin gene cluster, egc, including seg, sei, sem, sen, seo, and sometimes seu, is located
on the genomic island vSAβ, which cannot be mobilized [17]. Moreover, some core genome-encoded
SAgs exist that are present in all S. aureus isolates, i.e., SElX, SElY, and SElZ.
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Figure 1. SAgs induce oligoclonal T cell activation by circumventing conventional antigen presentation
pathways. (A) Upon uptake, conventional antigens are processed into short peptides and presented on
MHC-II molecules to CD4+ T cells. Only those rare T cells with the complementary TCR specificity
will be activated (one out of 104–105). (B) In contrast, SAgs circumvent this highly specific interaction
by directly cross-linking TCRs and MHC-II molecules outside their peptide binding sites, resulting in
oligoclonal T cell activation. MHC-II: Major histocompatibility complex class-II, TCR: T cell receptor,
SAg: Superantigen, APC: Antigen presenting cell. Arrows indicate the sequence of events.
Due to their locations on MGEs and the vSAβ island, the SAg gene repertoire of clinical S. aureus
isolates is highly diverse, and even closely related isolates can differ in their SAg gene patterns [18]. The
distribution of the SAg-carrying MGEs across the different S. aureus lineages is not random. In fact, each
lineage is characterized by a more or less restricted SAg gene pattern. For instance, the vSAβ-encoded
egc SAgs are strictly linked to the clonal background. Moreover, the transfer of MGE-encoded SAgs is
limited to certain lineages due to lineage-specific restriction/modification systems. Both mechanisms
contribute to lineage-specific rather than random SAg repertoires.
SAg gene expression is tightly regulated. While most SAg genes are transcribed in the stationary
growth phase in vitro, egc SAgs are expressed at low bacterial densities [17,19,20]. This differential
regulation might explain why humans rarely harbor antibodies against these SAgs, while serum
immunoglobulin (Ig) G antibodies against non-egc SAgs are very common, even in the healthy
population [19,21]. Which SAg genes are expressed under atopic conditions in vivo is still largely
unknown. However, the available data suggest that SAg genes may be expressed during symptom-free
colonization as well as under atopic conditions. For instance, our group determined the expression
profiles of three SAgs in S. aureus directly isolated from the nose of healthy persistent carriers and
observed that sea, sec, and the egc SAg selo were all expressed during nasal colonization [22]. Similarly,
tst transcripts were detected in the nose of a healthy carrier by RNAseq analysis [23]. In addition,
SAgs were detected within nasal polyp tissue in patients with chronic rhinosinusitis (CRS) [24,25].
More recently, more than 600 proteins released by S. aureus were identified by high resolution mass
spectrometry in the upper airway of patients with CRS; among these were also SEs [26]. Finally, SEA
was expressed by S. aureus Newman cultivated in lung surfactant [27]. Overall, these studies suggest
that SAg genes are indeed expressed under atopic conditions in vivo.
The 26 known staphylococcal SAgs share between 15.5% to 90% sequence homology on the
protein level [28]. Despite this variable degree of homology, all SAgs share a similar three-dimensional
structure, consisting of two globular domains, and the same binding partners [6,29,30]. Recent
structural studies, however, have revealed that SAgs are able to crosslink MHC-II molecules and TCRs
in a variety of ways [31]. This pronounced diversity of interactions hampers the development of a
universal SAg vaccine. Only SAg vaccines that target several specific binding domains will be able to
induce cross-protection against many SAgs.
Vaccine development against staphylococcal SAgs is also hindered by another property: Due
to their highly specific interaction with conserved regions of MHC alleles and TCR variants, these
toxins act to some degree host specific. For instance, compared to human T cells, the SAg’s mitogenic
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activity is reduced by a factor of 100–1000 in murine and rat-derived T cells [11,19,32,33]. The only
known susceptible animal species to develop human-like enterotoxigenic disease upon SAg exposure
are non-human primates [30]. This host-specific activity limits the range of animal models suitable for
studying SAg vaccines.
1.3. SAgs Can Induce Various Clinical Pictures
SAgs can trigger a range of clinical pictures, including toxinoses. The most frequent SAg-induced
toxinosis is staphylococcal food poisoning, characterized by nausea and violent vomiting, which is
usually self-limiting [30]. SAgs are highly stable molecules, resistant to heat, low pH, and digestion by
pepsin and trypsin [33]. Hence, SAgs produced by staphylococci on raw food are able to endure the
cooking process and transit the acidic stomach without damage. Upon entering the gut, SAgs probably
bind to a yet unidentified receptor on the surface of the submucosal mast cells and induce 5-HT release.
5-HT subsequently depolarizes the vagal afferent nerves resulting in stimulation of the brain stem
emetic loci to initiate the vomiting reflex [30].
Once they enter circulation in sufficient amounts, SAgs can trigger the toxic shock syndrome
(TSS). TSS is an acute and potentially fatal illness characterized by a high fever, diffuse erythematous
rash, hypotension, involvement of three or more organ systems, as well as desquamation of the
skin one to two weeks after onset (if not fatal before this time) [34]. This rare toxinosis involves the
release and systemic spread of SAgs from local infection sites, mostly from the vagina as a result of
tampon misusage, but also from infected wounds [34]. After entering the circulation, these toxins
trigger massive systemic T cell activation and cytokine release, leading to fever, inflammation, vascular
leakage, hypotension, multiorgan injury, and sometimes eventually death. TSS is a rare disease as
most humans have high titers of neutralizing serum antibodies [35–37].
2. Vaccination against SAgs
SAgs are of interest as vaccine candidates due to their implications in bacterial pathogenesis and
the lack of causal treatment strategies for SAg-induced diseases. However, due to their extremely high
mitogenic activity, only fragments or toxoids, i.e., SAg mutants lacking the ability to cross-link TCR
and MHC-II, can be used for vaccination. The structure–function relationship of several SAgs has
been resolved in the past 25 years [6,38–44]. On that basis, inactivating mutations have been predicted
and experimentally confirmed for a number of staphylococcal SAgs [45–47]. The development of
detoxified SEB and TSST-1 mutants is most advanced [48,49]. An effective vaccine against SAgs would
encompass the detoxified antigen in combination with adjuvants that stimulate a robust antibody
response necessary for direct neutralization of the toxin and an appropriate T cell response targeted at
clearing the pathogen [50].
Early vaccination studies with SAgs in animal models showed promising results in terms of
protection against SAg-induced diseases. For instance, mice vaccinated with a SEA mutant with
strongly reduced MHC-II binding and diminished mitogenic activity (SEA Y92A) were protected from
subsequent lethal SEA-induced toxic shock [51]. Similarly, another SEA mutant (SEA D227A) devoid
of toxic properties induced neutralizing antibodies and provided protection against SEA-induced
emesis in house musk shrews [52]. There is also evidence that SAg vaccines can protect against S.
aureus infections. Several studies demonstrated that vaccination with SAg toxoids provided protection
from subsequent S. aureus sepsis in mice and rabbits [53–56].
The protective immunity induced by vaccination with SAg toxoids seems to depend on both
anti-SAg antibodies and T cells. Indeed, there is strong evidence for a protective role of neutralizing
anti-SAg antibodies: While more than 90% of healthy adults have high anti-TSST-1 antibody titers, these
are absent in 90% of patients with menstruation-associated TSS [34,37]. Similarly, transfer of serum
from SAg-vaccinated mice to naive mice conferred partial protection from S. aureus infection [53,57]. T
cells also contribute to protection via IL-17-dependent mechanisms [58]. Therefore, an effective SAg
toxoid vaccine would elicit both neutralizing anti-SAg antibodies and protective SAg-specific T cell
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responses. Antibodies are required to neutralize the toxicity of SAgs and dampen the inflammatory
response early on during an infection while allowing Th17 cells to take action and clear the infection [47].
Moreover, any SAg toxoid vaccines should be adjuvanted and/or administered in a way that induces a
protective Th1/Th17 response while preventing unwanted Th2/Treg responses.
The high variability of SAgs on the protein level, however, impedes vaccine development against
SAgs [28]. There is evidence from both animal experiments and human studies that the adaptive
immune system meticulously differentiates between the numerous SAg proteins [35,59–62]. For
instance, SAg-vaccinated mice mount an antibody response that is specific for the vaccine SAg but is 10
times less effective against other SAgs [61]. Similarly, S. aureus carriers harbor highly specific anti-SAg
antibodies that neutralize the SAgs of their colonizing strains, but are less (or not at all) effective against
other SAgs [35]. Thus, vaccinating with a single SAg toxoid is probably not sufficient for effective
protection against all SAgs. A way out could be targeting the immune response to conserved residues,
for instance by a synthetic SAg vaccine. In fact, a synthetic SAg vaccine based on two conserved regions
within the staphylococcal SAgs induced antibodies that neutralized the mitogenic activity of five tested
S. aureus SAgs in vitro. Interestingly, the synthetic SAg peptide also acts as an inhibitor by binding
tightly to the MHC-II molecule. Application of the peptide 2 and 1 h before SAg challenge rescued
the mice from SEB- and TSST-1-induced lethality [63]. Recently, administration of a fusion protein
(TBA225) consisting of three toxoids, TSST-1, SEB, and SEA, protected mice against the challenge with
any of these three SAgs in a murine toxic shock model [64]. Polyclonal antibodies raised in rabbits
against this vaccine efficiently neutralized the superantigenicity of the vaccine SAgs and showed strong
cross-reactivity to SEC and SEH. However, their ability to neutralize other SAgs, including SED, SEE,
and SEK, was reduced by a factor of 10–100 [64]. To conclude, despite promising recent advances in
preclinical vaccine research there is still some work to be done to reach the grail of a cross-neutralizing
vaccine against all S. aureus SAgs.
To date, a TSST-1 toxoid (double mutant G31R-H135A) and an SEB toxoid (triple mutant
L45R-Y89A-Y94A), both supplemented with aluminum hydroxide adjuvant, have been tested in phase
1 clinical trials. Both studies showed the vaccines to be safe and well tolerated among healthy vaccines
(Table 1) [48,49]. Moreover, both toxoids were still immunogenic and induced a neutralizing antibody
response. These studies represent an important step in the development of SAg vaccines. However,
since S. aureus produces a plethora of toxins apart from SAgs, a vaccine targeting only SAgs might not
provide broad protection against a challenging pathogen like S. aureus. Hence, vaccination studies
should include SAgs along with other virulence factors in a multivalent vaccine [47].
Toxins 2020, 12, 176 6 of 21
Table 1. Clinical trials involving active vaccination with SAg toxoids or passive vaccination with therapeutic antisera.
Vaccination Type Target Name (Company; NCTNumber 1) Study Design Status and Study Results Intervention Duration Ref.
Active SEB 2
STEBVax
(Integrated BioTherapeu-
tics; NCT00974935)
Non-randomized, dose
escalation
Phase I, completed.
STEBvax was safe,
well-tolerated and
immunogenic,
induced/boosted
toxin-neutralizing antibodies
STEBVax vaccine 3 with
Alhydrogel adjuvant, six
doses (10 ng–20 µg) or
20 µg given in two
vaccinations 21 days apart
02/11-
03/15 [48]
Active TSST-1 4
rTSST-1v 5 (Biomedizi-
nische Forschungs
GmbH; NCT02340338)
Randomized,
double-blind, adjuvant-
controlled dose
escalation
Phase I, completed.
rTSST-1v was safe,
well-tolerated, and
immunogenic,
induced/boosted
toxin-neutralizing antibodies
rTSST-1 variant 5 with
Al(OH)3,
six doses in one to two
vaccinations (100 ng–30 µg)
06/14-
06/15 [49]
Active TSST-1
rTSST-1v (Biomedizi-
nische Forschungs
GmbH; NCT02814708)
Randomized, placebo-
controlled Phase II, ongoing
rTSST-1 variant 3 with
Al(OH)3,
two doses (10, 100 µg) in one
to three vaccinations
Since 03/16 -
Passive SAgs
IVIG 6
(Hospices Civils de
Lyon; NCT02219165)
Randomized, placebo-
controlled Phase II, completed
IVIG (single dose,
2 g/kg) Since 01/15 -
1 ClinicalTrials.gov Identifier (https://clinicaltrials.gov/), 2 SEB, staphylococcal enterotoxin B, 3 STEBVax is a recombinant detoxified version of the SAg SEB lacking toxic and superantigenic
properties. The mutant contains mutations in the hydrophobic binding loop (L45R), the polar binding pocket (Y89A), and the disulfide loop (Y94A), thereby disrupting the interaction of
the toxin with human MHC-II molecules. 4 TSST-1, toxic shock syndrome toxin 1, 5 TSST-1variant (TSST-1v) is a recombinant detoxified version of the SAg TSST-1 lacking toxic and
superantigenic properties. The double mutation G31R-H135A impairs rTSST-1v binding to both MHC-II molecules and to the TCR. 6 IVIG, intravenous immunoglobulins.
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3. SAgs and Allergy
3.1. Epidemiological Evidence for SAg Involvement in Allergy
S. aureus can frequently be found in the nasal passages and on the skin of healthy people, but
is reported to be even more frequent on the mucosal and skin surfaces in allergic rhinitis, asthma,
CRS, and atopic dermatitis patients [65]. While approximately 20% of the healthy population are
persistent carriers of S. aureus [1], patients with airway diseases show significantly higher rates of
S. aureus colonization with up to 90% in patients with nasal polyps, with the highest prevalence in
patients with comorbid asthma and aspirin sensitivity [66,67]. Furthermore, in the upper airways, S.
aureus may grow intramucosally and even reside intracellularly [68,69]. S. aureus cells within nasal
polyp tissue release numerous toxins and immune evasion molecules into the local environment,
including SAgs but also staphylococcal serine protease-like (Spl) proteins, which are also suspected
to play a role in allergies [26,70,71]. When the bacterium comes in contact with the immune system,
specific IgG antibodies are formed against different bacterial components. However, in a type 2-biased
local immune reaction, SEs, but also Spls and other immune active proteins may also give rise to the
formation of IgE antibodies [70,72]. In particular, the presence of SE-IgE has been associated with the
severity of any of the mentioned airway and skin diseases [73,74].
The presence of S. aureus and its allergenic components in home dust extracts has broadened the
range of possible sources for contact with these bacteria. The SAgs SEA, SEB, and SEC were found in
36–60% of the house dust samples [75]. House dust mites, that live in close association with humans,
obviously act as carriers for S. aureus and thus IgE-reactive bacterial antigens [76]. Moreover, sea-sed
genes were detected in bedroom dust in 21% to 63% of samples [77].
There is accumulating evidence today that SE-IgE is present in a relevant subgroup of patients
suffering from upper and lower type 2 airway diseases [4,78,79]. In a multicenter European study, 2908
subjects representative of the general population answered questionnaires on their disease, underwent
skin prick tests (SPT) for common aeroallergens, and provided blood for measurement of total serum
IgE and serum SE-IgE, using a mix of three staphylococcal superantigens (SEA, SEC, and TSST-1) [80].
From the results, 29.3% of the population was positive for SE-IgE with significant geographic variation.
SE-IgE was more common in smokers with ≥15 pack years (OR 1.70, 95% confidence interval (CI)
1.34–2.60 p < 0.001). Moreover, SE-IgE was associated with asthma (OR 2.10, 95% CI 1.60–2.76, p
= 0.001) in a serum concentration-dependent manner (OR 1.20, 1.74, 2.57 for the first, second, and
third tertile, respectively, above 0.10 kUA/L; kilounits of allergen-specific IgE per liter) independent
of the SPT results for inhalant allergens. Total IgE concentrations were higher in those with positive
SE-IgE than in those with positive SPT. This was the first study to show that SE-IgE is significantly and
independently associated with asthma in the general population.
In a smaller asthma cohort, SE-IgE positivity in serum was significantly more frequent in patients
with severe asthma than in healthy control subjects (60 vs. 13%, p < 0.001) [67]. Logistic regression
analyses demonstrated significantly increased risks for SE-IgE positive subjects compared to negative
subjects to have any asthma (OR 7.25, 95% CI 2.7–19.1; p < 0.001) or severe asthma (OR 11.09, 95%
CI 4.1–29.6; p < 0.001) [67], whereas grass pollen- or house dust mite-specific IgE was not associated
with any risk. SE-IgE in asthmatics was associated with significantly increased oral steroid use, more
frequent hospitalizations within the last year, and a lower lung function (FEV1% predicted value).
SE-IgE can be found in atopic and non-atopic patients; in non-atopic asthma, total serum IgE levels
were significantly increased in patients sensitized to SEs compared to patients non-sensitized to
SEs. Out of 224 patients with non-atopic and/or late-onset asthma, 47% patients were sensitized to
SEs [81]. The study concluded that SE sensitization may contribute to Th2-mediated inflammation in
non-atopic patients.
Song et al. reported similar observations from Korea. Serum SE-IgE concentrations were
significantly higher in asthmatics than controls [66]. Elderly asthma patients with high SE-IgE levels
had more severe asthma, sputum eosinophilia, and CRS compared to those with lower SE-IgE levels.
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The IDENTIFY study was conducted in Germany and focused on severe asthmatics previously
considered to be non-atopic based on a standard SPT [82]. In the non-atopic asthma group (n = 188),
allergic sensitization to at least one allergen was additionally detected in 52% of patients, with the
most frequent sensitizations to the SAgs SEB (app. 25%) and SEA (app. 15%); 8% of the patients were
mono-sensitized to SEA or SEB. This still may be an underestimation of sensitizations to S. aureus SAgs,
as the species harbors 26 SAg genes, of which only two have been tested.
In a nested case-control study using the 20-year Epidemiological study on the Genetics and
Environment of Asthma (EGEA) cohort, including 225 adults, SE sensitization varied between 39% in
controls to 58% and 76% in mild and severe asthma, respectively [83]. SE sensitization was associated
with an increased risk for severe asthma (adjusted OR 2.69, 95% CI 1.18–6.15) and asthma exacerbations
(adjusted OR 4.59, 95% CI 1.40–15.07) assessed 10 to 20 years later. This study confirmed the increased
SE-IgE positivity in asthmatics and its association to asthma severity and for the first time demonstrated
the predictive power of SE-IgE. Being sensitized to SEs—in contrast to inhalant allergens—is associated
with an increased risk of subsequently developing severe asthma and asthma exacerbations.
In a Korean study, serum IgE to SEA, SEB, and TSST-1 were detected more frequently in patients
with allergic rhinitis and asthma (21–27%) compared to allergic rhinitis patients without asthma
(11–21%) and healthy subjects (2–5%) [84]. Similarly, in Japan, 25% of patients with allergic rhinitis
were sensitized to SEA/SEB vs. 6.3% of controls [85]. In a meta-analysis of 10 studies, patients with
asthma (OR 3.3, 95% CI: 1.6–7.1, p = 0.002) and allergic rhinitis (OR 2.4, 95% CI: 1.3–4.7, p = 0.008)
were significantly more likely than controls to be SE-IgE positive [86]. Studies from Norway [87]
have shown an association between S. aureus carriage and severe allergic disease as well as allergic
multimorbidity. A total of 868 participants of a school-based cohort in late adolescence (aged 18–19
years) showed SE-IgE in serum in 26.2%; SE sensitization, but not S. aureus carriage, was associated
with poly-sensitization to food and inhalant allergens. SE-sensitized participants also had higher
median specific IgE to inhalant allergens, but not to food allergens.
Recently, in the “Learning Early About Peanut Allergy (LEAP)” study, participants’ eczema
severity was assessed, skin/nasal swabs were cultured for S. aureus, and sensitization to peanut and
egg was determined by serum-specific IgE and SPTs [88]. S. aureus skin colonization was significantly
associated with eczema severity across the LEAP study, whereas at 12 and 60 months of age, it was
related to subsequent eczema deterioration. Skin S. aureus colonization was further associated with
increased levels of egg white and peanut-specific IgE independent of eczema severity. Participants
with S. aureus were more likely to have persistent egg allergy and peanut allergy at 60 and 72 months
of age independent of eczema severity. All but one of the nine participants with a peanut allergy were
colonized at least once with S. aureus. Thus, S. aureus is associated with food sensitization and allergy
already early in life.
In summary, several clinical studies show that being sensitized to SEs—in contrast to inhalant
allergens—is associated with an increased risk of allergic sensitization and disease severity in patients
with chronic inflammatory airway diseases. The molecular mechanisms by which SAgs trigger or
amplify allergic immune responses, however, are not yet fully understood.
3.2. Interactions of SAgs with Immune Cells
SAgs of S. aureus can interact with the human immune system in multiple ways. By activating
various immune cell types, they contribute not only to the virulent but also to the allergenic character
of this bacterium. The following paragraphs provide an overview on the possible modes of SAg action.
3.2.1. Interaction with T Cells and APCs as SAg and Conventional Antigen
The term “superantigen” refers to the toxins’ ability to bypass the MHC-II-restricted antigen
presentation to T cells by directly cross-linking APCs and T cells independent of the antigen specificity
of the T cell (Figure 2A). This does not require SAg uptake and proteolytic processing, but rather
depends on its three-dimensional structure. A SAg initially binds to the APC’s MHC-II α- and/or
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β-chain outside the antigen presentation site and subsequently cross-links it to the TCR on the T cell. In
this process, the SAg binds primarily to the TCR’s variable region of the β-chain (Vβ-domain) (or Vα
in the case of SEH) [6,32,89]. Each SAg can attach to a characteristic subset of these Vβ elements, which
defines its Vβ signature [90]. This Vβ restriction results in an oligoclonal T cell activation [91]. In this
manner MHC-II- as well as MHC-I-restricted T cell populations can be targeted, eventually activating
up to 20% of T cells [28,92]. Moreover, TSST-1 and SEB contribute to this hyperinduction not only by
cross-linking MHC-II molecules and TCRs, but also by stimulating the interaction between CD28 on
T cells and its coligand CD86 on APCs. This enhancement was vital for eliciting an inflammatory
cytokine response [93,94]. On the APC side, SAgs differ greatly in their binding ability to different
MHC-II alleles [95]. SEA was shown to possess two binding sites for MHC-II molecules, enabling
attachment to two such molecules on the APC’s surface, which might explain its strong mitogenic
potential on T cells [96].
However, SAgs are also conventional antigens (Figure 2B). In fact, many of them are
immunodominant, as shown by high specific serum antibody titers in naturally exposed humans [35,36].
In this setting, SAg proteins are taken up by APCs, processed into short peptides, and presented in an
MHC-II-restricted manner to T cells. In this case, only SAg-specific Th cells, i.e., those that specifically
recognize the SAg peptide in complex with the MHC-II molecule, will get activated. To date, it has
not been possible to study SAg-specific Th cells because the strong superantigenic activity of these
toxins will overwhelm any antigen-specific response in T cell cultures.However, with the availability
of SAg toxoids it will now be possible to enumerate and characterize them.The high frequency of class
switched SAg-specific B cells, which is discussed below, strongly implies the existence of SAg-specific
T cells, because B cell class switch requires the help of a Th cell recognizing the same antigen.
3.2.2. Interactions with B Cells as SAgs and Conventional Antigens
The conventional antigen-specific T cell-dependent B cell activation, termed ‘cognate interaction’
between the two cell types, requires three signals. The first signal is delivered by the B cell’s binding of
an antigen with its specific B cell receptor (BCR). The antigen is then taken up, processed, and peptides
are presented on MHC-II molecules to T cells for their activation [97]. The cognate T cell binds with its
TCR, upregulates CD40L on its surface, and secretes cytokines [98]. The second and third signals are
the ligation of CD40 on the B cell and the binding of cytokines, respectively, which trigger signaling
cascades in the B cell leading to its clonal expansion, differentiation, and Ig secretion [99]. Whereas
naïve mature B cells express IgD and IgM on their surfaces, T cells help can induce a class switch to
IgG, IgA, or IgE. The Ig classes differ in their biological functions, which is important for adapting
the humoral immune responses to different antigenic challenges [100,101]. For example, the control
of extracellular bacteria or worms requires special immune effector functions that are triggered by
specific IgG and IgE, respectively. T cell help via CD40L is required for the Ig class switch in B cells.
Finally, T cell help for B cells initiates the affinity maturation of the antibody response, which is caused
by somatic hypermutation of the antibody genes [102,103].
SAgs circumvent the antigen-specific interaction between T helper cells and B cells by directly
cross-linking MHC-II molecules on B cells with TCRs on T cells (Figure 2C). The T cells would then be
activated in a Vβ-specific manner to express CD40L [104] and cytokines which then drive polyclonal B
cell activation independent of the antigen-specificities of the T and B cells involved. However, this
mechanism of polyclonal B cell activation by SAgs is controversial because experiments have yielded
inconsistent results. Several groups have observed inhibition rather than activation of Ig-secreting cells
through SAgs in vitro and in vivo, which was T cell-dependent [105–108]. In contrast, polyclonal B cell
activation and differentiation into Ig-secreting plasma cells was observed in cell cultures containing
irradiated T cells unable to proliferate. The ratio of B and T cells also influenced the outcome. Cultures
with a ratio of 5:1 B/T cells showed highest Ig production, whereas a higher proportion of T cells
reduced the Ig production [109]. Other groups found Ig secretion in cultures when they used very low
concentrations of SAgs [110,111]. In conclusion, SAgs can be potent polyclonal activators of B cells
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under conditions that do not elicit strong T cell proliferation. Whether this scenario also takes place
in vivo remains to be clarified.
Figure 2. SAgs interact with immune cells in various ways, leading to oligoclonal or antigen-specific
activation of T and B cells. (A) SAgs cross-link APCs and T cells regardless of the specificity of the TCR,
leading to a Vβ-restricted, oligoclonal T cell activation. (B) SAgs can be taken up and processed by
APCs and subsequently presented as conventional antigens on MHC-II molecules to T cells. T cells
whose TCRs are specific for the SAg can bind the MHC:peptide complex and become activated. (C) In
this special case of SAg-induced immune cell activation, B cells act as APCs. By cross-linking, T cells
are activated in a Vβ-restricted manner, as described in A. Moreover, the cross-linked B cells receive
activation signals regardless of their B cell receptor (BCR) specificity. This results in the polyclonal
B cell activation and the production of polyclonal antibodies. (D) SAg-specific B cells bind SAgs via
their BCR, followed by processing and subsequent presentation to T cells as conventional antigens
on MHC-II molecules. The activated SAg-specific T cells will provide T cell help to the presenting B
cells, resulting in B cell activation, plasma cell differentiation, and the release of specific antibodies
against the encountered SAg. (E) If SAgs cross-link B cells with Th2 cells, the latter are activated in a
Vβ-restricted manner and release type 2 cytokines (e.g., interleukin 4 (IL-4)). IL-4 can induce a class
switch to immunoglobulin E (IgE) in the cross-linked B cells, resulting in the production of polyclonal
IgE. To designate this hitherto unrecognized feature of SAgs, we propose the term ‘T cell-dependent
superallergen’. (F) SAgs can also act as conventional allergens. In this scenario, SAg-specific B cells
bind SAg via their BCR followed by processing and subsequent presentation as conventional antigens
on MHC-II molecules to Th2 cells. The activated SAg-specific Th2 cell will provide B cell help and
release IL-4, which induces class switch to IgE and the production of specific antibodies against the
encountered SAg. Green background color: There is strong scientific evidence for interaction. Red:
There is currently only limited evidence for this interaction. Arrows indicate sequence of events.
It is clear, however, that SAgs can be recognized by B cells as conventional antigens and induce
the production of SAg-specific antibodies (Figure 2D). This implies that SAg-specific B cells bind
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SAgs via their BCR, internalize and process them, and present the resulting peptides in an MHC-II
restricted manner to SAg-specific T cells. These provide cognate T cell help, resulting in B cell
activation and the release of class-switched specific anti-SAg antibodies. In fact, class-switched
SAg-neutralizing antibodies are highly prevalent in the sera of adults [112]. Moreover, the high
specificity of these antibodies for their inducing SAg indicates affinity maturation, which also requires
T cell help [35,57,61,63].
3.2.3. Interaction with B Cells as Superallergens and Conventional Allergens
On the basis of epidemiological data (see Section 3.1) and the results of mechanistic studies
(see Section 3.2), SAgs are attributed an important role in allergy by initiating or amplifying type 2
responses. Apart from activating Th2 cells in a Vβ-restricted manner (Figure 2A), SAgs might also
polyclonally stimulate IgE-positive B cells or even induce a class switch to IgE (Figure 2E). This scenario
represents a special case of the SAg-induced polyclonal B cell activation, depicted in Figure 2C. In
this—hypothetical—scenario the Th2 cells release IL-4, IL-5, IL-9, and IL-13 [113] and upregulate
CD40L upon Vβ-restricted cross-linking of their TCRs with MHC-II molecules on B cells [114]. IL-4 or
IL-13 in combination with direct contact to activated T cells via CD40/CD40L drives an Ig class switch
to IgE [115]. Thereby, SAgs could initiate or amplify a polyclonal IgE response regardless of the B cells’
antigen specificity.
Several studies corroborate the ability of SAgs to drive polyclonal IgE production. For instance,
TSST-1 was shown to induce CD40L expression on oligoclonally activated T cells and to induce IgE
synthesis in vitro in a dose-dependent manner. Notably, this IgE synthesis was dependent on direct
contact between B and T cells via CD40/CD40L [104]. Furthermore, Hofer and co-workers showed that
during the pollen season restimulation of in vivo-primed peripheral blood mononuclear cells with
TSST-1 enhanced the allergen-specific IgE production in vitro. This effect was dependent on the ratio of
IFNγ and IL-4 in the cell culture. During the pollen season the endogenous IL-4 level was sufficient to
induce allergen-specific IgE. In contrast, outside the pollen season the addition of exogenous IL-4 was
required to induce IgE secretion due to high endogenous INFγ levels [116]. Moreover, sensitization
against SEs was observed to be significantly associated with poly-sensitization against various food
and inhalant allergens [87]. We propose the term ‘T cell-dependent superallergen’ to designate this
SAg function as a stimulus of B cell poly-sensitization. This concept is distinct from the term “B cell
superallergen”, which refers to bacterial or viral proteins that can cross-link conserved structures
on IgE thereby triggering the antigen-independent activation and degranulation of mast cells and
basophils, which are decorated with IgE via their Igε receptors [117,118].
Finally, the observation of SE-IgE demonstrates that SAgs can also act as conventional allergens
(Figure 2F). This implies that they are recognized by specific B cells, taken up, processed, and presented
to specific Th2 cells. These provide B cell help and release the pro-allergenic cytokine IL-4 to induce a
class switch to IgE, resulting in the production of SE-IgE. Allergen-specific IgE is crucial for specific
downstream stimulation of mast cells and basophils causing allergic symptoms.
Recently, Spls were identified as allergens of S. aureus [4,70,71]. The immune response against
these proteases is characterized by the formation of high titers of specific IgE, release of type 2
cytokines in healthy individuals, and eosinophilic infiltration in the airways upon intratracheal Spl
exposure in mice [70]. Similarly, a mutant, non-superantigenic variant of SEC was shown to induce
a type 2 cytokine response in mice after subcutaneous injection [55]. Moreover, SAg-specific IgE in
patients with atopic dermatitis or airway diseases were observed in different cohorts as described
above [72,119–123]. In addition, in nasal polyp mucosal tissue, SEs caused the release of cytokines
supporting type 2 inflammation, especially IL-2, IL-4, and IL-5 whereas IL-10 and TGF-β1 were
disfavored [124]. Therefore, SAgs appear to have a dual role in allergy, acting on the one hand as
T cell-dependent superallergens causing poly-sensitization and on the other hand driving a type 2
immune response as conventional allergens.
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3.2.4. Interaction with Other Immune Cells
Staphylococcal SAgs are well-known for their ability to cross-link TCRs and MHC-II molecules
and induce oligoclonal T cell activation. However, these molecules can also affect other immune cell
types involved in allergy. For instance, SEB can directly cause degranulation of cutaneous mast cells
in monkeys [125] and in a rodent RBL-2H3 mast cell line [126]. Similarly, in house musk shrews and
marmosets, SEA binds to submucosal mast cells in the gut and triggers degranulation [127,128]. This
occurs via an yet-unknown receptor on the mast cells and is independent of MHC-II [30]. When SEB
and viable S. aureus were added to explanted mucosal tissue from CRS patients, the bacterium was
phagocytosed by mast cells and caused mast cell rupture and degranulation. The rate of mast cell
degranulation was significantly lower when S. aureus was added alone, demonstrating a prominent
role for SEB in the uptake of S. aureus and mast cell degranulation [129].
Little is known about direct effects of SAgs on eosinophils and basophils. Basophils from AD
patients can recognize SAg-IgE complexes via their FcεRI receptor and release histamine [119]. It was
also reported that, similar to SpA, SEE has an IgE binding site that targets a conserved framework region
of IgE antibodies. Hence, SEE could trigger mast cells and basophils by crosslinking the SEE-specific
antigen binding site on one IgE molecule and the conserved framework region on another [130].
4. How Does S. aureus Benefit from Producing SAgs?
Despite more than 30 years of research, the advantage gained by S. aureus from SAgs is still under
discussion. SAgs are thought to create an immunological smokescreen through stimulating the release
of a storm of cytokines that makes T cells refractory to specific activation. Thus, S. aureus can hide from
specific immune recognition [9]. Also, T cells exposed to the cytokine storm become anergic and many
of them ultimately die [131,132]. Hence, one could speculate that the net effect of SAgs is the reduction
of the T cell repertoire including the elimination of S. aureus-reactive T cells.
It is also discussed that SAgs promote S. aureus’ host colonization. SAgs are found in nasal
polyp tissues [25,26], their transcripts have been detected in S. aureus isolated from the nose of
carriers [22], and antibodies directed against SAgs are elevated in persistent carriers [22,29,35]. TSST-1
vaccination reduced the bacterial load in a murine colonization model, presumably by inducing
neutralizing antibodies [58]. In another mouse model, in contrast, deletion of SAg genes increased
the S. aureus burden [133]. To resolve this paradox, it was proposed that SAgs act as a checkpoint
for innocuous colonization. By promoting a local inflammatory response that keeps the bacterial
density below the pathogenic threshold, SAgs foster asymptomatic carriage, while preventing complete
elimination by the immune system [89]. Collectively, these data indicate that SAgs are important for
maintaining colonization.
Finally, we have summarized the evidence that SAgs drive a Th2 immune response which can
manifest itself in allergy. Driving an allergic inflammation favors S. aureus because such a response
counteracts the Th1/17 profile, which effectively clears extracellular bacteria. Th1 responses promote
macrophage activation and intracellular elimination of phagocytosed bacteria, while Th17 responses
initiate neutrophil maturation and recruitment, and they enhance epithelial and mucosal barrier
functions [50]. Thus we have proposed that type 2 immunity, which can be promoted by SAgs,
represents an immune evasion mechanism [4,134]. It is, therefore, not surprising to notice that the rate
of colonization of S. aureus among allergic patients, such as atopic dermatitis and CRS, is significantly
higher than in healthy individuals [4,135,136]. It is conceivable that type 2 immune modulation by
S. aureus also increases the risk of infections by this microorganism as well as by other bacteria or
enhances their severity [137].
Overall, it seems like S. aureus has evolved a plethora of SAgs with multiple functions: (1) create
a “smokescreen” that prevents mounting a specific T cell response against these bacteria, (2) foster
colonization, and (3) promote an allergenic environment within the host that increases the survival
chances of the bacterium.
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5. Open Questions
The data compiled in this review show that there is growing evidence for a role of SAg in inducing
and amplifying allergic responses, and possible mechanisms, both evidence-based and hypothetical, are
provided. However, this review also pinpoints open questions that should be addressed in the future:
• Currently, specific IgE antibodies can be measured against four different SAgs, SEA–SEC, and
TSST-1, using commercial tests. To evaluate the potential roles of the other 22 SAgs in allergic
diseases the appropriate assays need to be established.
• SAg-specific T cells, i.e., those that specifically recognize a SAg peptide in complex with a MHC-II
molecule, have not been studied to date. To understand their role in allergic diseases, however, it is
crucial to determine the quality of the natural T cell response against SAgs in healthy individuals
and patients. With the availability of SAg toxoids and sophisticated T cell assays, this will now
be feasible.
• T cell-dependent superallergens are thought to stimulate B cells of any specificity to form IgE.
However, evidence to support this notion of SAg-mediated polysensitization is scarce.
• Considering the high prevalence of anti-SAg antibodies, including SE-IgE, it is likely that most
individuals are primed with S. aureus SAgs and have generated an anti-SAg T cell response, which
may comprise substantial numbers of Th2 cells. Vaccination with SAg toxoids without adjuvant
might enhance this pre-existing Th2 bias in susceptible individuals, thereby exacerbating allergy
rather than inducing protection. To avoid this, the SAg-specific T cells responses have to be
studied in healthy individuals and patient cohorts.
• After more than 30 years of research, the evolutionary advantages gained from SAgs are still
under discussion. Using SAg-knock-out strains or SAg vaccines in animal models could help to
scrutinize their role in colonization and infection.
• Since SAgs likely play an important role in allergic disorders, future research should enforce
efforts to develop broadly cross-reactive SAg vaccines or SAg antagonists.
6. Closing Remarks
There is strong epidemiological evidence for an involvement of S. aureus SAgs in allergic diseases.
Patients with airway diseases show significantly higher rates of S. aureus colonization than healthy
individuals. Moreover, SE-IgE can be found in a relevant subgroup of patients suffering from upper
and lower type 2 airway diseases. Notably, only sensitization to SEs but not inhalant allergens is
associated with an increased risk of developing severe asthma and asthma exacerbations in the future.
However, the molecular mechanisms by which SAgs trigger or amplify allergic immune responses
are not yet fully understood. SAgs could have a dual role in allergies, acting on the one hand as
T cell-dependent superallergens causing B cell poly-sensitization, and on the other hand driving a
type 2 immune response as conventional allergens. In addition, SAgs could directly trigger mast
cell degranulation and hence exacerbate allergic symptoms. Future research should address the IgE
response against all known S. aureus SAgs, decipher the natural T cell response to SAgs as conventional
antigens as well as their potential role as superallergens. A better understanding of the role of SAgs in
atopy might guide the development of novel diagnostic and therapeutic tools for upper and lower
type 2 airway diseases.
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